IPSEF News and Press, Ipsen Sa Ord From 12/07/23

PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today...

ELATIVE ® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis. Elafibranor demonstrates significant improvements in biomarkers of disease progression versu...

2023-10-26 03:55:25 ET More on Ipsen S.A., Ipsen S.A., etc. Exelixis lead product hits main goal in Phase 3 prostate cancer trial Ipsen wins FDA approval of rare bone disease drug palovarotene Historical earnings data for Ipsen S.A. Dividend scorecard for Ips...

Paris (France), 26 October 2023 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023. Sales and pipeline highlights Total-sales growth in the year to da...

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay ® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023 Committee for Orphan Medicinal Products confirms a negative ...

PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for liquid botulinum toxin type A (QM-1114), noting certain deficienci...

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...

PARIS, FRANCE, 4 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Pascal Touchon to its Board as an independent director, effective 4 October 2023, following the decision of Paul Sekhri to step down from his director role on this date due to other pro...

PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Christelle Huguet as Executive Vice President, Head of Research and Development. She will succeed Howard Mayer, EVP and Head of R&a...